Altering the course of heart failure with carotid body modulation
This article was originally published in Start Up
Cibiem Inc.’s catheter-based CBM system is designed to modulate the carotid body, a tiny group of chemoreceptors located at the fork of the carotid artery that helps regulate respiratory activity. The start-up believes its technology could mean new treatment possibilities for a broad range of diseases including heart failure, where it could address the remodeling that takes place as well as alleviate such symptoms as breathlessness.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
COVID-19 has not held back GSK's preparations to create the world's largest standalone consumer health business, with CEO Emma Walmsley confirming separation is on track for summer next year.